MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

In vaccines, sales of HPV vaccines — Gardasil and Gardasil 9 — fell 40% to $1.33 billion ... Sales of the pneumococcal 15-valent conjugate vaccine Vaxneuvance rose 7% to $230 million ...

vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s second-highest selling product. During MSD’s Q1 2025 earnings call on 24 April, chief financial officer Caroline ...

Sales Grew 10% GARDASIL/GARDASIL 9 Sales Declined 41% to $1.3 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 40% GAAP EPS Was $2.01; Non-GAAP EPS Was $2.22 Presented Compelling ...

GARDASIL/GARDASIL 9 sales fell ~41% YoY to $1.3B following a ~17% YoY drop in Q4 2024, mainly due to lower demand in China. Meanwhile, Winrevair, a treatment the company markets with Bristol Myers ...

The drugmaker is still dealing with the fallout over its HPV vaccine Gardasil in China, where a drop in demand forced it to halt shipments and rescind its previous forecast of $11 billion in ...

Merck , known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025. "Our company made strong progress to start the year, with increasing ...